Modulation of the NO-cGMP-PDE5 pathway is reported in COVID-19 patients for developing pulmonary fibrosis and inflammation in the lung and cardiovascular disorders [54, 55]. This evidence concerns the gene PDE5A and cardiovascular disorder.